Literature DB >> 10965098

Taxol resistance.

S Sangrajrang1, A Fellous.   

Abstract

BACKGROUND: Taxol has gained considerable attention in cancer therapy in recent years and is successfully used in treating a variety of tumors, including those of the breast, ovary and lung. Despite its preclinical and clinical success, the ability of tumors to develop an acquired resistance to drugs used for treatment remains a major obstacle to cancer cure. A better understanding of the various mechanisms of Taxol resistance may have important implications for strategies designed for cancer treatment.
METHOD: This review summarizes the information available to date concerning the effects of Taxol and the development of drug resistance, focusing particularly on alterations in microtubules. RESULTS AND DISCUSSION: Acquired resistance to Taxol is a function of multiple adaptations. Although the cellular transport of Taxol appears to be an important mechanism of resistance to Taxol, altered transcription and posttranslational modification of microtubular changes may be involved in the mechanism of drug resistance. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965098     DOI: 10.1159/000007306

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  11 in total

1.  Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP).

Authors:  Weihong Guo; Zhian Chen; Xiaoli Feng; Guodong Shen; Huilin Huang; Yanrui Liang; Bingxia Zhao; Guoxin Li; Yanfeng Hu
Journal:  J Nanobiotechnology       Date:  2021-05-19       Impact factor: 10.435

2.  Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance.

Authors:  Yuan Tian; Aik-Choon Tan; Xiaer Sun; Matthew T Olson; Zhi Xie; Natini Jinawath; Daniel W Chan; Ie-Ming Shih; Zhen Zhang; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2009-11       Impact factor: 3.494

3.  Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.

Authors:  Qiang-Ling Sun; Hui-Fang Sha; Xiao-Hua Yang; Guo-Liang Bao; Jing Lu; Yin-Yin Xie
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-25       Impact factor: 4.553

4.  Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

Authors:  Ozgur Kutuk; Anthony Letai
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1.

Authors:  Zhigang Bai; Zhongtao Zhang; Xiang Qu; Wei Han; Xuemei Ma
Journal:  Oncol Lett       Date:  2011-09-09       Impact factor: 2.967

6.  Activation of acetyl-coenzyme A carboxylase is involved in Taxol-induced ovarian cancer cell death.

Authors:  Jiang Wu; Fang Ji; Wen DI; Hongduo Chen; Yinsheng Wan
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

7.  miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.

Authors:  Liqin Du; Maria C Subauste; Christopher DeSevo; Zhenze Zhao; Michael Baker; Robert Borkowski; Jeoffrey J Schageman; Rachel Greer; Chin-Rang Yang; Milind Suraokar; Ignacio I Wistuba; Adi F Gazdar; John D Minna; Alexander Pertsemlidis
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

8.  The nature of the modification at position 37 of tRNAPhe correlates with acquired taxol resistance.

Authors:  Yu Pan; Tong-Meng Yan; Jing-Rong Wang; Zhi-Hong Jiang
Journal:  Nucleic Acids Res       Date:  2021-01-11       Impact factor: 16.971

Review 9.  Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.

Authors:  Hend M Nawara; Said M Afify; Ghmkin Hassan; Maram H Zahra; Akimasa Seno; Masaharu Seno
Journal:  Biomedicines       Date:  2021-05-02

Review 10.  The Application of Citrus folium in Breast Cancer and the Mechanism of Its Main Component Nobiletin: A Systematic Review.

Authors:  Yuan Wu; Chien-Shan Cheng; Qiong Li; Jing-Xian Chen; Ling-Ling Lv; Jia-Yue Xu; Kai-Yuan Zhang; Lan Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-29       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.